Vivosim Lab Inc (VIVS)

$1.58 -0.04 (-2.47%)
Market Cap 4.23M
Revenue (ttm) 140,000.00
Net Income (ttm) -2.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,771.43%
Debt to Equity Ratio 0.00
Volume 29,500
Avg Vol 2,031,376
Day's Range N/A - N/A
Shares Out 2.61M
Stochastic %K 53%
Beta 1.43
Analysts Strong Buy
Price Target $64.83

Company Profile

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicolo...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 224 1000
Website: vivosim.ai
Address:
11555 Sorrento Valley Road, Suite 100, San Diego, United States
PIBBuckeye
PIBBuckeye Apr. 1 at 7:52 PM
$VIVS Straight up after an ATM offering. 🤣
0 · Reply
Drugtrade
Drugtrade Apr. 1 at 12:54 PM
$VIVS same old scam
0 · Reply
DARKP00L
DARKP00L Apr. 1 at 12:10 PM
$VIVS 08:08 on Apr. 01 2026 VivoSim Labs Announces The Pricing Of Up To A $4M Best-Efforts Public Offering, With $3M Funded At An Initial Closing Of The Offering #tradeideas
0 · Reply
Forlix
Forlix Mar. 30 at 5:08 PM
Thank you so much @Stocktwits for adding/updating these logos! $VIVS $ABTC $ZONE $MSTR $LEU
0 · Reply
MGAP
MGAP Mar. 24 at 7:44 PM
$VIVS ?
0 · Reply
MGAP
MGAP Mar. 24 at 4:27 PM
$VIVS guide us now god
0 · Reply
MGAP
MGAP Mar. 24 at 4:26 PM
$VIVS unmmm
0 · Reply
Stonk_Junkie
Stonk_Junkie Mar. 24 at 1:24 PM
$VIVS what red on news?
0 · Reply
Yacuzma
Yacuzma Mar. 24 at 1:03 PM
$VIVS just a little pop on the news this morning? damn
0 · Reply
MGAP
MGAP Mar. 24 at 12:44 PM
$VIVS ?
0 · Reply
Latest News on VIVS
VivoSim Announces Pricing of up to a $4 Million Public Offering

Apr 1, 2026, 8:05 AM EDT - 7 days ago

VivoSim Announces Pricing of up to a $4 Million Public Offering

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

Mar 24, 2026, 8:05 AM EDT - 15 days ago

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

Mar 3, 2026, 8:05 AM EST - 5 weeks ago

VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

Feb 11, 2026, 8:05 AM EST - 2 months ago

VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

Jan 29, 2026, 4:05 PM EST - 2 months ago

VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

Jan 6, 2026, 8:05 AM EST - 3 months ago

VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

Aug 14, 2025, 8:05 AM EDT - 8 months ago

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

May 13, 2025, 8:05 AM EDT - 11 months ago

VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

May 7, 2025, 8:05 AM EDT - 1 year ago

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

Apr 24, 2025, 8:05 AM EDT - 1 year ago

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

VivoSim to Carry Forward Organovo 3D Bioprinting

Apr 23, 2025, 8:05 AM EDT - 1 year ago

VivoSim to Carry Forward Organovo 3D Bioprinting

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

Apr 2, 2025, 8:05 AM EDT - 1 year ago

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

Organovo Provides Business Update

Mar 27, 2025, 8:05 AM EDT - 1 year ago

Organovo Provides Business Update

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Mar 25, 2025, 11:25 AM EDT - 1 year ago

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

LLY

Organovo Announces Reverse Stock Split

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Organovo Announces Reverse Stock Split

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

GRCE MTNB

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Mar 6, 2025, 8:05 AM EST - 1 year ago

Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Feb 25, 2025, 8:05 AM EST - 1 year ago

Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Jan 6, 2025, 8:05 AM EST - 1 year ago

Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Nov 20, 2024, 8:05 AM EST - 1 year ago

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Nov 13, 2024, 8:06 AM EST - 1 year ago

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

Jul 18, 2024, 7:55 AM EDT - 1 year ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Jul 16, 2024, 8:05 AM EDT - 1 year ago

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

May 21, 2024, 8:05 AM EDT - 2 years ago

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

May 14, 2024, 11:00 AM EDT - 2 years ago

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

May 8, 2024, 8:00 PM EDT - 2 years ago

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Organovo's fatty liver disease drug meets main goal in mid-stage study

Apr 15, 2024, 8:28 AM EDT - 2 years ago

Organovo's fatty liver disease drug meets main goal in mid-stage study

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Apr 15, 2024, 8:05 AM EDT - 2 years ago

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress

Jan 25, 2024, 8:05 AM EST - 2 years ago

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

Jan 9, 2024, 8:05 AM EST - 2 years ago

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

Dec 6, 2023, 8:05 AM EST - 2 years ago

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

Nov 13, 2023, 8:05 AM EST - 2 years ago

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

Organovo Highlights FXR314 Combination Therapy Potential and Plan

Nov 8, 2023, 8:05 AM EST - 2 years ago

Organovo Highlights FXR314 Combination Therapy Potential and Plan

Organovo to Participate in the H.C. Wainwright Global Investment Conference

Sep 8, 2023, 12:46 PM EDT - 2 years ago

Organovo to Participate in the H.C. Wainwright Global Investment Conference

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Aug 23, 2023, 8:05 AM EDT - 2 years ago

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Announces FXR Program

Mar 21, 2023, 8:05 AM EDT - 3 years ago

Organovo Announces FXR Program

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates

Nov 15, 2022, 8:05 AM EST - 3 years ago

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug Candidates

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:20 AM EDT - 3 years ago

Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Organovo Announces Postponement of Annual Meeting of Stockholders

Sep 6, 2022, 8:05 AM EDT - 3 years ago

Organovo Announces Postponement of Annual Meeting of Stockholders

Organovo Achieves 3D Tissue Model for Crohn's Disease

May 17, 2022, 8:05 AM EDT - 4 years ago

Organovo Achieves 3D Tissue Model for Crohn's Disease

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Mar 1, 2022, 8:05 AM EST - 4 years ago

UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Feb 23, 2022, 8:05 AM EST - 4 years ago

Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2022, 4:00 PM EST - 4 years ago

Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Organovo Welcomes New Sr. Vice President of Strategy and Business Development

Feb 18, 2022, 1:00 PM EST - 4 years ago

Organovo Welcomes New Sr. Vice President of Strategy and Business Development

Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents

Feb 2, 2022, 12:00 PM EST - 4 years ago

Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents

Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk

Jan 10, 2022, 12:00 PM EST - 4 years ago

Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk

Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022

Nov 30, 2021, 8:05 AM EST - 4 years ago

Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022

Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Sep 17, 2021, 4:10 PM EDT - 4 years ago

Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Catherine Wood's ARK Investment Slashes Organovo Holding

Mar 11, 2021, 3:58 PM EST - 5 years ago

Catherine Wood's ARK Investment Slashes Organovo Holding

Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)

Mar 2, 2021, 8:05 AM EST - 5 years ago

Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)

PIBBuckeye
PIBBuckeye Apr. 1 at 7:52 PM
$VIVS Straight up after an ATM offering. 🤣
0 · Reply
Drugtrade
Drugtrade Apr. 1 at 12:54 PM
$VIVS same old scam
0 · Reply
DARKP00L
DARKP00L Apr. 1 at 12:10 PM
$VIVS 08:08 on Apr. 01 2026 VivoSim Labs Announces The Pricing Of Up To A $4M Best-Efforts Public Offering, With $3M Funded At An Initial Closing Of The Offering #tradeideas
0 · Reply
Forlix
Forlix Mar. 30 at 5:08 PM
Thank you so much @Stocktwits for adding/updating these logos! $VIVS $ABTC $ZONE $MSTR $LEU
0 · Reply
MGAP
MGAP Mar. 24 at 7:44 PM
$VIVS ?
0 · Reply
MGAP
MGAP Mar. 24 at 4:27 PM
$VIVS guide us now god
0 · Reply
MGAP
MGAP Mar. 24 at 4:26 PM
$VIVS unmmm
0 · Reply
Stonk_Junkie
Stonk_Junkie Mar. 24 at 1:24 PM
$VIVS what red on news?
0 · Reply
Yacuzma
Yacuzma Mar. 24 at 1:03 PM
$VIVS just a little pop on the news this morning? damn
0 · Reply
MGAP
MGAP Mar. 24 at 12:44 PM
$VIVS ?
0 · Reply
Dev214
Dev214 Mar. 24 at 12:31 PM
$VIVS great news with very high ctb and at atl price, shorts will find hard to cover. Last time it ran 200% from these levels
0 · Reply
premarketmaker
premarketmaker Mar. 24 at 12:23 PM
$VIVS $2.10+ for the squeeze Nice movement/
0 · Reply
DARKP00L
DARKP00L Mar. 24 at 12:21 PM
$VIVS 08:20 on Mar. 24 2026 VivoSim Labs Announces Its NAMkind Liver, Intestine Models Validated For Predicting Toxicity, Side Effect Profiles Of Antibody Drug Conjugates #tradeideas
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 24 at 12:16 PM
$VIVS VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
0 · Reply
MGAP
MGAP Mar. 24 at 12:13 PM
$VIVS news
0 · Reply
MGAP
MGAP Mar. 19 at 7:49 PM
$VIVS in
0 · Reply
Drew613
Drew613 Mar. 17 at 12:20 PM
$VIVS coming up this weekend. Society of Toxicology (“SOT”) meeting in San Diego, CA that takes place March 22-25 and present new data on its NAMkind™ liver and NAMkind™ Intestine model, including data on validating the models for use in predicting toxicity and side effect profiles of antibody drug conjugates (ADCs). Should draw attention and upward move imo.
2 · Reply
Drew613
Drew613 Mar. 8 at 9:50 PM
$VIVS
0 · Reply
Victory777777
Victory777777 Mar. 8 at 5:58 PM
$VIVS $5
0 · Reply
waterhunter1
waterhunter1 Mar. 5 at 11:42 PM
$VIVS rebranded garbage stock, garbage leadership, garbage "product" operating on lies and scam tech.
0 · Reply
gooofy
gooofy Mar. 4 at 9:08 PM
$VIVS volume is shot.. lol
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 10:50 PM
$VIVS RSI: 65.82, MACD: 0.0095 Vol: 0.25, MA20: 2.12, MA50: 2.04 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply